| Date | Title | Description |
| 11.04.2024 | Nuevocor Strengthens Leadership Team with Appointment of John Lee as Chief Medical Officer | SINGAPORE and PHILADELPHIA, April 11, 2024 /PRNewswire/ -- Nuevocor, a pre-clinical stage biotechnology company dedicated to developing novel medicines to treat cardiomyopathies with aberrant mechanobiology, today announces the appointment ... |
| 30.11.2021 | Slone Partners Places Jonathan Birchall as Chief Commercial Officer at PhaseBio Pharmaceuticals | “Jonathan Birchall is a respected leader with a history of building highly successful commercial operations at dynamic biotech and pharmaceutical companies,” said Slone Partners Chief Executive Officer (CEO) Leslie Loveless.
SOUTH RIDING, V... |
| 22.06.2021 | Alfasigma acquires the European license for bentracimab from PhaseBio | BOLOGNA, Italy, 22 giugno 2021 /PRNewswire/ -- Alfasigma has entered into an exclusive licensing agreement with PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), for the commercialization of bentracimab in 49 countries across Europe and other ... |
| 15.03.2021 | PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights | MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--Mar 15, 2021--
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary ... |
| 11.03.2021 | PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab | MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--Mar 11, 2021--
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary ... |
| 19.10.2018 | PhaseBio goes public in downsized offering of $46 million | On Sept. 5, the company announced the closure of a Series D financing round worth $34 million, with participation from new investors Cormorant Asset Management, Rock Springs Capital and Mountain Group Partners. Existing investors include Ne... |
| 05.09.2018 | PhaseBio Secures $34 Million in Series D Financing | MALVERN, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, with an initial focus on ca... |
| 05.09.2018 | PhaseBio nets $34M to advance Brilinta reversal agent, PAH drug | PhaseBio raised $34 million in its series D round, which will advance its lead assets: a treatment for pulmonary arterial hypertension (PAH) developed in-house and a reversal agent of AstraZeneca’s clot-busting Brilinta, licensed from the B... |
| 05.09.2018 | PhaseBio nets $34M to advance Brilinta reversal agent, PAH drug | PhaseBio raised $34 million in its series D round, which will advance its lead assets: a treatment for pulmonary arterial hypertension (PAH) developed in-house and a reversal agent of AstraZeneca’s clot-busting Brilinta, licensed from the B... |
| 05.09.2018 | PhaseBio Secures $34M in Series D Financing | PhaseBio Pharmaceuticals, Inc., a Malvern, PA-based clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, with an initial focus on cardiopulmonary disorders, closed... |
| 09.03.2018 | Outsourcing veteran Jamie Macdonald takes the helm at Parexel; CSO Rosana Kapeller exits Nimbus | Josef von Rickenbach
→ Top-10 CRO Parexel has brought in an experienced hand to take the helm. Co-founder Josef von Rickenbach — a familiar face in the outsourcing world — is stepping up to concentrate on the chairman’s spot... |
| 30.11.2017 | PhaseBio Pharmaceuticals Secures $15.6m in Funding | PhaseBio Pharmaceuticals, Inc., a Malvern, PA-based clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, secured $15.6m in funding.
The company entered into a $7.5m term loan facility with Sili... |
| 29.11.2017 | J&J disputes report it’s dropping JLabs plans for UK; Takeda takes Zika vaccine into PhI | → The Telegraph reported that J&J is planning to pull the plug on its plans to open a JLabs facility in the UK, citing the political and economic uncertainty around Brexit. But a company spokesperson tells me it’s al... |
| 12.03.2015 | PhaseBio Raises $40 Million Series C Financing | - |
| 12.03.2015 | PhaseBio Pharmaceuticals Secures $40M in Series C Funding | PhaseBio Pharmaceuticals Inc., a Malvern, Pennsylvania-based company focused on developing treatments for metabolic and specialty cardiopulmonary disorders, secured $40m in Series C funding.
The round was led by AstraZeneca with participati... |
| 21.08.2012 | Type 2 diabetes drug with goal of 24/7 glycemic control begins Phase 2b trial | The biotechnology firm raised $48.4 million earlier this year in its third tranche for its series B financing round led by New Enterprise Associates with participation by Hatteras Venture Partners, Johnson & Johnson Development Corp., A... |
| 06.06.2012 | Hyperglycemia drug developer raises $25 million to advance pipeline | Prior added that the results of its long-acting drug for hyperglycemia were so compelling it wants to compare it with the current gold standard treatment in the upcoming phase 2b clinical trial. Victoza is a once-daily treatment produced by... |
| 05.06.2012 | PhaseBio Pharma Receives Additional $23M |
MALVERN, PA, Clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced that it has raised a total of $48.4 million from its Series B financing.
>> Click here fo... |
| 05.06.2012 | PhaseBio Pharmaceuticals Received an Additional $23 Million with Completion of the Third Tranche of a Series B Financing for Advancement of Metabolic and Cardiovascular Product Portfolio | - |
| 15.11.2011 | Hyperglycemia drug gets positive results in clinical trial | GLP-1 analogues that have been approved by the U.S. Food and Drug Administration need to be given at least once a day, said Lynne Georgopoulos, senior vice president of clinical development. “Our intent was to develop a long-acting drug tha... |
| 03.12.2010 | Diabetes, cardiovascular drug developer PhaseBio adds $15M | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R... |
| 02.12.2010 | PhaseBio Pharmaceuticals Raises $15M in Series B Financing | PhaseBio Pharmaceuticals, Inc., a Malvern, Pennsylvania-based clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, has raised $15m in Series B financing.
This final close, wh... |
| 07.01.2010 | PhaseBio Pharmaceuticals Raises $25M in Series B Funding Round | PhaseBio Pharmaceuticals, Inc., a Research Triangle Park, NC-based company focusing on the discovery and development of therapeutic fusion proteins, has raised $25m in a Series B financing round.
New investors New Enterprise Associates (NEA... |
| 07.01.2010 | PhaseBio Pharmaceuticals, Inc. Raises $25 Million in Series B Funding, Initiates Collaboration with OSI Pharmaceuticals | - |
| - | Type 2 diabetes drug with goal of 24/7 glycemic control begins Phase 2b trial | A biotechnology company developing a long-acting drug for hyperglycemia associated with type 2 diabetes has initiated a multisite Phase 2b trial, according to a company statement.
PhaseBio Pharmaceuticals‘ lead drug Glymera is a recombinant... |
| - | PhaseBio Pharmaceuticals to Host Virtual Investor and Analyst Day on March 15, 2021 | MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--Feb 24, 2021--
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary ... |
| - | PhaseBio goes public in downsized offering of $46 million | A biotechnology company developing therapies for pulmonary arterial hypertension and for bleeding in patients taking antiplatelet therapy has made its initial public offering, albeit at a downsized price.
Malvern, Pennsylvania-based PhaseBi... |
| - | PhaseBio Announces Proposed Public Offering of Common Stock | MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--Mar 17, 2021--
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary ... |
| - | PhaseBio Announces Pricing of Public Offering of Common Stock | MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--Mar 17, 2021--
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary ... |
| - | Hyperglycemia drug developer raises $25 million to advance pipeline | A biotechnology company developing a long-acting drug and insulin to treat hyperglycemia in people with type 1 and type 2 diabetes, and a treatment for hypertension has raised $25 million in a series B financing round.
The investment for th... |
| - | Hyperglycemia drug gets positive results in clinical trial | PhaseBio Pharmaceuticals‘ phase I/IIa clinical study for its drug, Glymera, for the treatment of hyperglycemia in patients with type 2 diabetes, met with positive results, according to a release from the company.
The single and multiple asc... |
| - | Diabetes, cardiovascular drug developer PhaseBio adds $15M | The Philadelphia-area biopharma company PhaseBio Pharmaceuticals has received the final $15 million of a $25 million investment to fund further testing of its lead drug, which focuses on hyperglycemia related to Type 2 diabetes.
The company... |
